Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a structured narrative review synthesizing evidence and international guidelines on surgical management of borderline resectable pancreatic cancer in the neoadjuvant therapy era, offering a practical decision-making framework rather than reporting original trial data.
A narrative review synthesizing current evidence on immunotherapy in advanced biliary tract cancer, highlighting established standards (TOPAZ-1, KEYNOTE-966), emerging biomarkers, and investigational approaches rather than reporting original trial results.
A single case report of advanced HCC with rupture treated with combination immunotherapy and successfully transplanted; demonstrates feasibility but lacks comparator, control group, and generalizability needed to establish efficacy or change practice.
A multi-algorithm machine learning signature study with external validation across four datasets and functional validation of a candidate gene, showing clear prognostic separation but limited by retrospective cohort design and surrogate endpoints rather than prospective clinical outcomes.
A multicenter retrospective real-world study with propensity weighting showing clinically meaningful improvements in response rates, PFS, and OS for a novel embolic agent versus standard care, but limited by retrospective design and real-world (non-randomized) conduct.
Retrospective observational study of 161 patients suggesting dose modifications do not compromise survival in second-line pancreatic cancer, but lacks randomization and prospective design to establish definitive practice guidance.
A narrative review synthesizing evidence on IDH inhibitors across multiple cancer types, discussing FDA-approved agents, clinical trial data, and resistance mechanisms—informative for clinical decision-making but not reporting original empirical results.
A single-centre retrospective analysis of a prospectively maintained database showing that CA 19-9 surveillance detects recurrence in gallbladder cancer with modest sensitivity (45.6% for serial rise) and high specificity (95.3%), with a median lead time of 5.4 weeks before radiological detection.